The efficacy of mangosteen pericarp fruit extract for the treatment of schizophrenia.

Phase 2

Completed

• Conditions: Schizophrenia; Mental Health - Schizophrenia; Alternative and Complementary Medicine - Other alternative and complementary medicine

• Registration Number: ACTRN12616000859482
• Lead Sponsor: niversity Hospital-Barwon Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-06-30
• Study Completion: 2019-02-15
• Last Update Posted: 25 May 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

1. Being 18 years or older
2. Have a DSM-V diagnosis of schizophrenia or schizoaffective disorder.
3. Score greater than or equal to 54 on the PANSS total score or have a CGI-S score of greater than or equal to 3.
4. Participants currently under therapy for schizophrenia or schizoaffective disorder will need to have been on that primary therapy for at least four weeks prior to randomization.
5. Have the capacity to consent to the study and comply with the procedures.
6. Be using effective contraception if female, sexually active and childbearing age.
7. Be able to speak, read, write and understand English language.
8. Participants will be required to nominate a current treating physician and will not be eligible to enter the study until one is identified.

Exclusion Criteria

1. Participants with a known or suspected active systemic medical disorder.
2. Individuals who are pregnant or lactating.
3. Participants currently enrolled in any other intervention study.
4. Individuals who are intolerant, allergic to or have had an anaphylactic reaction to any of the components of the preparation.
5. Inability to comply with either the requirements of informed consent or treatment protocol.

Study & Design

• Study Type: Interventional
• Study Design: Not specified